查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1945795

女性健康市场－全球产业规模、份额、趋势、机会及预测（按药物、应用、地区和竞争格局划分，2021-2031年）

Women's Health Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球女性健康市场预计将从 2025 年的 167.6 亿美元成长到 2031 年的 254.9 亿美元，复合年增长率为 7.24%。

该领域涵盖一系列针对女性特有疾病的药品、医疗设备和诊断技术，例如妇科癌症、生殖健康问题和自体免疫疾病。推动该领域成长的主要因素是女性人口老化以及需要持续临床管理的慢性疾病负担日益加重。例如，美国癌症协会 (ACS) 估计，到 2024 年，美国将新增 310,720 例浸润性乳癌病例，这凸显了对能够支撑市场稳定的医疗解决方案的迫切且普遍的需求。

市场概览
预测期 2027-2031
市场规模：2025年 167.6亿美元
市场规模：2031年 254.9亿美元
复合年增长率：2026-2031年 7.24%
成长最快的细分市场 女性不孕症
最大的市场 北美洲

儘管有这些积极迹象，但由于长期资金短缺和复杂的法规环境，市场仍面临许多障碍。女性生物学研究的资金筹措通常高于其他治疗领域，这成为创新的瓶颈。资源分配不均，加上临床试验的高成本，阻碍了新治疗方法的商业化。因此，资金和监管方面的挑战有可能延缓重要医疗解决方案的推出，并限制市场充分满足全球患者群体多样化需求的能力。

市场驱动因素

女性健康科技和数位健康领域的创新蓬勃发展，正成为市场成长的重要催化剂，并正在改变生殖健康和一般医疗保健的提供方式。透过整合人工智慧和行动连线，该领域正在提供个人化的生育管理、月经週期追踪和更年期支援解决方案，以弥合医疗服务获取方面的差距，并减少对传统医疗机构的依赖。 2024年7月，Flo Health获得由General Atlantic主导的2亿美元C轮融资，用于提升其预测能力。此举证实了消费者工具的商业性可行性，并凸显了该技术作为医疗保健基础设施核心要素的扩充性。

政府政策和增加对女性健康研究的投入，正有助于进一步稳定和加速该产业的发展。国家主导正积极应对长期存在的资金短缺问题，降低早期研究在孕产妇健康和子宫内膜异位症等被忽视领域的风险。例如，2024年2月，美国国防高级研究计画局（ARPA-H）承诺投入1亿美元用于突破性的女性健康研究，从而支持高风险、高回报的计划。 2024年，世界经济论坛指出，到2040年，消除性别健康差距每年可为全球经济贡献1兆美元，这将为系统性投资提供强大的经济动力。

市场挑战

长期存在的资金分配不均严重限制了女性健康市场的发展，限制了可用于研发的资金。这种资金分配不均造成了创新瓶颈，使製药和医疗设备公司难以透过昂贵的临床试验推出新型治疗方法。因此，针对女性生理特征的治疗方法研发面临重大延误，限制了慢性病有效管理策略的普及。

投资不足的后果体现在全球研究经费中分配给该领域的比例极低。世界经济论坛预测，到2024年，除癌症以外的女性疾病的医疗保健研发投资仅占医疗保健研发总投资的1%。如此微薄的资金限制了市场多元化发展和满足未被满足的需求的能力。因此，该领域未能充分发挥其商业性潜力，导致全球很大一部分患者无法获得足够的治疗选择。

市场趋势

生殖和荷尔蒙健康家庭诊断检测的普及正在改变市场格局，它分散了医疗服务，并克服了临床就诊障碍。在对隐私和便利性的需求驱动下，这一趋势使患者能够在家中进行重要的筛检，例如子宫颈癌和性行为感染感染的筛检。对于那些往往避免接受传统骨盆检查的低频检测族群而言，自取样检测显着提高了他们的依从性。 2025年4月，Labcorp推出了一项获得FDA核准的全国性解决方案，用于为未接受常规HPV检测的人群提供阴道内自取样HPV检测。

同时，非荷尔蒙避孕技术的研发和商业化正成为一股重要趋势，满足了那些希望在不承受荷尔蒙副作用的情况下进行计划生育的患者的需求。这一趋势的重点是长效可逆避孕方法（LARCs），这些方法利用先进材料确保在无需全身激素干预的情况下也能有效避孕。这些创新为那些不适合或无法接受荷尔蒙避孕的女性提供了必要的替代方案。 2025年1月，Sebela Pharmaceuticals宣布，其无激素铜子宫内避孕器Copper 175mm²在3期临床试验中达到了0.94的珍珠指数，证明了这些新型解决方案的有效性。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球女性健康市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依药物类型（Prolia、Xava、Evista、Mirena、 Zometa等）
    • 用途（女性不孕症、停经后骨质疏鬆症、子宫内膜异位症、避孕、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

6. 北美女性健康市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲女性健康市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区女性健康市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东与非洲女性健康市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

10. 南美洲女性健康市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球女性健康市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • AbbVie, Inc
  • Bayer AG
  • Merck & Co., Inc
  • Pfizer, Inc
  • Teva Pharmaceutical Industries Ltd
  • Amgen, Inc
  • Apothecus Pharmaceutical Corp
  • Blairex Laboratories, Inc
  • Ferring BV
  • Agile Therapeutics

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 19868

The Global Women's Health Market is projected to expand from USD 16.76 Billion in 2025 to USD 25.49 Billion by 2031, registering a CAGR of 7.24%. This sector comprises a wide array of pharmaceuticals, medical devices, and diagnostics designed for conditions specifically affecting women, including gynecological cancers, reproductive health issues, and autoimmune diseases. Growth is primarily driven by an aging female demographic and the rising burden of chronic pathologies, which require ongoing clinical management. For instance, the American Cancer Society estimated 310,720 new invasive breast cancer cases in the U.S. in 2024, highlighting the essential, non-discretionary demand for medical solutions that underpins market stability.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 16.76 Billion
Market Size 2031USD 25.49 Billion
CAGR 2026-20317.24%
Fastest Growing SegmentFemale Infertility
Largest MarketNorth America

Despite these positive indicators, the market faces significant hurdles due to historical funding gaps and complex regulatory environments. Research into female-specific biology has often received less capital than other therapeutic areas, creating an innovation bottleneck. This inequitable resource allocation, compounded by high clinical trial costs, hinders the commercialization of new treatments. Consequently, financial and regulatory challenges threaten to slow the rollout of essential healthcare solutions, thereby limiting the market's ability to fully address the diverse needs of the global patient population.

Market Driver

The surge in FemTech and digital health innovations acts as a major catalyst for market growth, transforming the delivery of reproductive and general care. By integrating artificial intelligence and mobile connectivity, this sector offers personalized solutions for fertility management, menstruation tracking, and menopause support, bridging access gaps and reducing dependence on traditional clinics. In July 2024, Flo Health secured a $200 million Series C investment led by General Atlantic to boost its predictive capabilities, a move that validates the commercial viability of direct-to-consumer tools and highlights technological scalability as a core element of the healthcare infrastructure.

Government policies and increased funding for women's healthcare research further stabilize and accelerate the industry. State-sponsored initiatives are actively addressing historic underfunding by de-risking early-stage research in neglected areas such as maternal health and endometriosis. For example, the Advanced Research Projects Agency for Health (ARPA-H) committed $100 million in February 2024 to fund novel female health research, enabling high-risk, high-reward projects. The World Economic Forum noted in 2024 that closing the gender health gap could add $1 trillion annually to the global economy by 2040, providing strong economic motivation for systemic investment.

Market Challenge

Historical funding disparities severely restrict the women's health market by limiting the capital available for research and development. This lack of equitable financial allocation creates an innovation bottleneck, complicating the efforts of pharmaceutical and medical device companies to push novel treatments through expensive clinical trials. As a result, the development of therapies tailored to female biology encounters significant delays, which restricts the availability of effective management strategies for chronic pathologies.

The consequences of this underinvestment are highlighted by the disproportionately small share of global research funding assigned to this sector. According to the World Economic Forum in 2024, only 1 percent of total healthcare R&D investment was allocated to female-specific conditions outside of oncology. This minimal financial commitment hampers the market's ability to diversify its portfolio and address unmet medical needs. Consequently, the sector struggles to reach its full commercial potential, leaving a large portion of the global patient population without adequate therapeutic options.

Market Trends

The proliferation of at-home diagnostic testing for reproductive and hormonal health is reshaping the landscape by decentralizing care and overcoming barriers to clinical access. Driven by a demand for privacy and convenience, this trend allows patients to conduct critical screenings for conditions like cervical cancer and sexually transmitted infections at home. Self-collection methods notably improve compliance among under-screened groups who may avoid traditional pelvic exams. In April 2025, Labcorp introduced a nationwide FDA-approved solution for self-collected vaginal HPV testing, targeting populations not up to date with recommended screenings.

Simultaneously, the development and commercialization of non-hormonal contraceptive innovations are becoming a critical force, addressing patient preferences for family planning without hormonal side effects. This trend focuses on long-acting reversible contraceptives (LARCs) that use advanced materials to ensure efficacy without systemic hormonal intervention. These innovations provide necessary alternatives for women contraindicated for or dissatisfied with hormonal options. In January 2025, Sebela Pharmaceuticals announced that their hormone-free Copper 175mm2 IUD achieved a Pearl Index of 0.94 in a Phase 3 study, validating the effectiveness of these novel solutions.

Key Market Players

  • AbbVie, Inc
  • Bayer AG
  • Merck & Co., Inc
  • Pfizer, Inc
  • Teva Pharmaceutical Industries Ltd
  • Amgen, Inc
  • Apothecus Pharmaceutical Corp
  • Blairex Laboratories, Inc
  • Ferring B.V.
  • Agile Therapeutics

Report Scope

In this report, the Global Women's Health Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Women's Health Market, By Drugs

  • Prolia
  • Xgeva
  • Evista
  • Mirena
  • Zometa
  • Others

Women's Health Market, By Application

  • Female Infertility
  • Post enopausal Osteoporosis
  • Endometriosis
  • Contraception
  • Others

Women's Health Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Women's Health Market.

Available Customizations:

Global Women's Health Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Women's Health Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Others)
    • 5.2.2. By Application (Female Infertility, Post enopausal Osteoporosis, Endometriosis, Contraception, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Women's Health Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drugs
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Women's Health Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drugs
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Women's Health Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drugs
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Women's Health Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drugs
        • 6.3.3.2.2. By Application

7. Europe Women's Health Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drugs
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Women's Health Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drugs
        • 7.3.1.2.2. By Application
    • 7.3.2. France Women's Health Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drugs
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Women's Health Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drugs
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Women's Health Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drugs
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Women's Health Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drugs
        • 7.3.5.2.2. By Application

8. Asia Pacific Women's Health Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drugs
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Women's Health Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drugs
        • 8.3.1.2.2. By Application
    • 8.3.2. India Women's Health Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drugs
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Women's Health Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drugs
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Women's Health Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drugs
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Women's Health Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drugs
        • 8.3.5.2.2. By Application

9. Middle East & Africa Women's Health Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drugs
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Women's Health Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drugs
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Women's Health Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drugs
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Women's Health Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drugs
        • 9.3.3.2.2. By Application

10. South America Women's Health Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drugs
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Women's Health Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drugs
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Women's Health Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drugs
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Women's Health Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drugs
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Women's Health Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie, Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bayer AG
  • 15.3. Merck & Co., Inc
  • 15.4. Pfizer, Inc
  • 15.5. Teva Pharmaceutical Industries Ltd
  • 15.6. Amgen, Inc
  • 15.7. Apothecus Pharmaceutical Corp
  • 15.8. Blairex Laboratories, Inc
  • 15.9. Ferring B.V.
  • 15.10. Agile Therapeutics

16. Strategic Recommendations

17. About Us & Disclaimer